| P50 | author | Talita M Marin | Q56875615 |
| P2093 | author name string | Michael Bauer | |
| | Bo Wang | |
| | Benjamin G Neel | |
| | Roderick Bronson | |
| | Maria I Kontaridis | |
| | Xue Wu | |
| | Kleber G Franchini | |
| | Benjamin Davies | |
| | David A Conner | |
| | Demetrios Kalaitzidis | |
| | Kimberly Keith | |
| | Jessica Lauriol | |
| | Prajna Guha | |
| P2860 | cites work | Leopard syndrome | Q21202917 |
| | Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome | Q24291893 |
| | Grouping of multiple-lentigines/LEOPARD and Noonan syndromes on the PTPN11 gene | Q24299557 |
| | Functional effects of PTPN11 (SHP2) mutations causing LEOPARD syndrome on epidermal growth factor-induced phosphoinositide 3-kinase/AKT/glycogen synthase kinase 3beta signaling | Q24304242 |
| | Reduced phosphatase activity of SHP-2 in LEOPARD syndrome: consequences for PI3K binding on Gab1 | Q24321087 |
| | Rapamycin selectively inhibits angiotensin II-induced increase in protein synthesis in cardiac myocytes in vitro. Potential role of 70-kD S6 kinase in angiotensin II-induced cardiac hypertrophy | Q71807337 |
| | Hypertrophic cardiomyopathy in Noonan syndrome | Q71967975 |
| | Rapamycin inhibits alpha 1-adrenergic receptor-stimulated cardiac myocyte hypertrophy but not activation of hypertrophy-associated genes. Evidence for involvement of p70 S6 kinase | Q73554710 |
| | Activation of mRNA translation in rat cardiac myocytes by insulin involves multiple rapamycin-sensitive steps | Q73630601 |
| | Noonan syndrome and aortic coarctation | Q77521849 |
| | Inhibition of mTOR reduces chronic pressure-overload cardiac hypertrophy and fibrosis | Q80027046 |
| | Microarray analysis of Akt1 activation in transgenic mouse hearts reveals transcript expression profiles associated with compensatory hypertrophy and failure | Q80044502 |
| | Two novel and one recurrent PTPN11 mutations in LEOPARD syndrome | Q80609337 |
| | Electrotonic modulation of cardiac impulse conduction by myofibroblasts. | Q48721222 |
| | Gain-of-function SOS1 mutations cause a distinctive form of Noonan syndrome. | Q52000174 |
| | Roles of growth hormone and insulin-like growth factor 1 in mouse postnatal growth. | Q52142765 |
| | Distinct molecular phenotypes in murine cardiac muscle development, growth, and hypertrophy. | Q52180073 |
| | [Rapamycin and CCI-779] | Q53805382 |
| | The face of Noonan syndrome: Does phenotype predict genotype. | Q55097554 |
| | PI3Kγ Modulates the Cardiac Response to Chronic Pressure Overload by Distinct Kinase-Dependent and -Independent Effects | Q57006372 |
| | Congenital intrahepatic portosystemic venous shunt: An unusual feature in LEOPARD syndrome and in neurofibromatosis type 1 | Q58193644 |
| | Cardiologic abnormalities in Noonan syndrome: phenotypic diagnosis and echocardiographic assessment of 118 patients | Q70503201 |
| | The Leopard (multiple lentigines) syndrome revisited | Q70746131 |
| | Mutation of SHOC2 promotes aberrant protein N-myristoylation and causes Noonan-like syndrome with loose anagen hair | Q24336157 |
| | Protein kinase cascades in the regulation of cardiac hypertrophy | Q24518494 |
| | Diversity and functional consequences of germline and somatic PTPN11 mutations in human disease | Q24540529 |
| | Cardiac remodelling: concentric versus eccentric hypertrophy in strength and endurance athletes | Q24653777 |
| | The docking protein Gab1 is the primary mediator of EGF-stimulated activation of the PI-3K/Akt cell survival pathway | Q24799816 |
| | Shp2 knockdown and Noonan/LEOPARD mutant Shp2-induced gastrulation defects | Q27314678 |
| | A restricted spectrum of NRAS mutations causes Noonan syndrome | Q27658480 |
| | Crystal structure of the tyrosine phosphatase SHP-2 | Q27748898 |
| | Gain-of-function RAF1 mutations cause Noonan and LEOPARD syndromes with hypertrophic cardiomyopathy | Q27865193 |
| | The 'Shp'ing news: SH2 domain-containing tyrosine phosphatases in cell signaling | Q28182148 |
| | Potential pharmacological interventions in polycystic kidney disease | Q28258516 |
| | Cardiac hypertrophy induced by mitogen-activated protein kinase kinase 7, a specific activator for c-Jun NH2-terminal kinase in ventricular muscle cells | Q28263599 |
| | Three-Dimensional Structures of Acidic and Basic Fibroblast Growth Factors | Q28267322 |
| | Mutations in the gene for cardiac myosin-binding protein C and late-onset familial hypertrophic cardiomyopathy | Q28268916 |
| | PTPN11 mutations and genotype-phenotype correlations in Noonan and LEOPARD syndromes | Q28275701 |
| | Germline gain-of-function mutations in SOS1 cause Noonan syndrome | Q28276979 |
| | The mTOR pathway and its role in human genetic diseases | Q28285976 |
| | PTPN11 (Shp2) mutations in LEOPARD syndrome have dominant negative, not activating, effects | Q28288812 |
| | Germline KRAS mutations cause Noonan syndrome | Q28297024 |
| | LEOPARD syndrome: clinical diagnosis in the first year of life | Q28300885 |
| | MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts | Q28511032 |
| | Rapid transcriptional activation and early mRNA turnover of brain natriuretic peptide in cardiocyte hypertrophy. Evidence for brain natriuretic peptide as an "emergency" cardiac hormone against ventricular overload | Q28568167 |
| | Mouse model of Noonan syndrome reveals cell type- and gene dosage-dependent effects of Ptpn11 mutation | Q28594140 |
| | Shp2 negatively regulates growth in cardiomyocytes by controlling focal adhesion kinase/Src and mTOR pathways | Q28854293 |
| | Congenital heart diseases in children with Noonan syndrome: An expanded cardiac spectrum with high prevalence of atrioventricular canal | Q29013212 |
| | A highly efficient recombineering-based method for generating conditional knockout mutations | Q29615157 |
| | Clinical proof-of-concept trial to assess the therapeutic effect of sirolimus in patients with autosomal dominant polycystic kidney disease: SUISSE ADPKD study | Q33299027 |
| | Rapamycin weekly maintenance dosing and the potential efficacy of combination sorafenib plus rapamycin but not atorvastatin or doxycycline in tuberous sclerosis preclinical models | Q33430534 |
| | Cardiac fibroblasts are essential for the adaptive response of the murine heart to pressure overload | Q33559670 |
| | Mammalian target of rapamycin is a critical regulator of cardiac hypertrophy in spontaneously hypertensive rats. | Q33576908 |
| | Rapamycin ameliorates PKD resulting from conditional inactivation of Pkd1. | Q33702386 |
| | Shp-2 tyrosine phosphatase: signaling one cell or many | Q33783500 |
| | Noonan syndrome: clinical aspects and molecular pathogenesis | Q33806161 |
| | Regulation of myocardial contractility and cell size by distinct PI3K-PTEN signaling pathways | Q39750571 |
| | Akt promotes survival of cardiomyocytes in vitro and protects against ischemia-reperfusion injury in mouse heart. | Q39870130 |
| | Recent Advances in the Molecular Genetics of Hypertrophic Cardiomyopathy | Q40467490 |
| | Molecular regulation of atrioventricular valvuloseptal morphogenesis | Q40549504 |
| | Molecular basis of familial cardiomyopathies | Q40559439 |
| | Noonan syndrome-associated SHP2/PTPN11 mutants cause EGF-dependent prolonged GAB1 binding and sustained ERK2/MAPK1 activation | Q40587895 |
| | The tyrosine phosphatase SHP-2 is required for mediating phosphatidylinositol 3-kinase/Akt activation by growth factors | Q40775807 |
| | The genetic basis of pediatric cardiovascular disease | Q41415560 |
| | SH2-containing phosphotyrosine phosphatase as a target of protein-tyrosine kinases | Q41566173 |
| | Revealing mechanisms for SH2 domain mediated regulation of the protein tyrosine phosphatase SHP-2. | Q41743522 |
| | Shp-2 mediates v-Src-induced morphological changes and activation of the anti-apoptotic protein kinase Akt. | Q41751641 |
| | Diverse biochemical properties of Shp2 mutants. Implications for disease phenotypes | Q42480603 |
| | Phosphatase-dependent and -independent functions of Shp2 in neural crest cells underlie LEOPARD syndrome pathogenesis | Q42591567 |
| | PTPN11 mutations in LEOPARD syndrome | Q43056955 |
| | Correlation between PTPN11 gene mutations and congenital heart defects in Noonan and LEOPARD syndromes. | Q43073992 |
| | Cardiac fibroblasts regulate myocardial proliferation through beta1 integrin signaling | Q43152071 |
| | Mammalian target of rapamycin and autosomal dominant polycystic kidney disease | Q43299411 |
| | Cardiac-specific overexpression of GLUT1 prevents the development of heart failure attributable to pressure overload in mice | Q44179204 |
| | Ras/Erk signaling is essential for activation of protein synthesis by Gq protein-coupled receptor agonists in adult cardiomyocytes | Q44201590 |
| | Activation of signal transducer and activator of transcription (STAT) pathways in failing human hearts. | Q44301871 |
| | Rapamycin attenuates load-induced cardiac hypertrophy in mice | Q44385669 |
| | Mutations in PTPN11 implicate the SHP-2 phosphatase in leukemogenesis | Q44673842 |
| | Genetic evidence for lineage-related and differentiation stage-related contribution of somatic PTPN11 mutations to leukemogenesis in childhood acute leukemia | Q44775999 |
| | Mutation screening of the PTPN11 gene in hypertrophic cardiomyopathy | Q46952138 |
| | Patient-specific induced pluripotent stem-cell-derived models of LEOPARD syndrome | Q33910479 |
| | Prognostic implications of novel beta cardiac myosin heavy chain gene mutations that cause familial hypertrophic cardiomyopathy | Q34120159 |
| | Combinatorial control of the specificity of protein tyrosine phosphatases | Q34180660 |
| | Akt/protein kinase B promotes organ growth in transgenic mice | Q34276940 |
| | Activation of multiple signaling pathways causes developmental defects in mice with a Noonan syndrome–associated Sos1 mutation | Q34360215 |
| | Altered glucose homeostasis in mice with liver-specific deletion of Src homology phosphatase 2 | Q34400843 |
| | PTPN11 mutations in Noonan syndrome: molecular spectrum, genotype-phenotype correlation, and phenotypic heterogeneity | Q34522913 |
| | Noonan syndrome and related disorders: genetics and pathogenesis | Q34560418 |
| | MEK-ERK pathway modulation ameliorates disease phenotypes in a mouse model of Noonan syndrome associated with the Raf1(L613V) mutation | Q34627221 |
| | Germline gain-of-function mutations in RAF1 cause Noonan syndrome | Q34644154 |
| | The role of the mammalian target of rapamycin (mTOR) in renal disease | Q34659391 |
| | Raptor and mTOR: Subunits of a Nutrient-Sensitive Complex | Q35560388 |
| | Functional analysis of leukemia-associated PTPN11 mutations in primary hematopoietic cells | Q35847802 |
| | Hypertrophic cardiomyopathy in childhood | Q35872427 |
| | Functional analysis of PTPN11/SHP-2 mutants identified in Noonan syndrome and childhood leukemia | Q36100102 |
| | The conserved phosphoinositide 3-kinase pathway determines heart size in mice | Q36246110 |
| | Phosphoinositide 3-kinase(p110α) plays a critical role for the induction of physiological, but not pathological, cardiac hypertrophy | Q36350066 |
| | Cardiac restricted overexpression of kinase-dead mammalian target of rapamycin (mTOR) mutant impairs the mTOR-mediated signaling and cardiac function | Q36646353 |
| | HRAS and the Costello syndrome | Q36717501 |
| | The genetics of congenital heart disease: a review of recent developments. | Q36782724 |
| | Signaling pathways mediating cardiac myocyte gene expression in physiological and stress responses | Q36798390 |
| | Role of ERK1/2 signaling in congenital valve malformations in Noonan syndrome | Q36999895 |
| | The tyrosine phosphatase Shp2 (PTPN11) in cancer. | Q37088972 |
| | Phosphatase-defective LEOPARD syndrome mutations in PTPN11 gene have gain-of-function effects during Drosophila development | Q37102143 |
| | Noonan syndrome cardiac defects are caused by PTPN11 acting in endocardium to enhance endocardial-mesenchymal transformation | Q37112471 |
| | Hypertrophic cardiomyopathy: current understanding and treatment objectives | Q37302532 |
| | Noonan, Costello and cardio-facio-cutaneous syndromes: dysregulation of the Ras-MAPK pathway | Q37343475 |
| | Gene recombination in postmitotic cells. Targeted expression of Cre recombinase provokes cardiac-restricted, site-specific rearrangement in adult ventricular muscle in vivo. | Q37369799 |
| | Evaluating temsirolimus activity in multiple tumors: a review of clinical trials | Q37645019 |
| | Genetic and pathogenetic aspects of Noonan syndrome and related disorders | Q37661298 |
| | Deletion of Ptpn11 (Shp2) in cardiomyocytes causes dilated cardiomyopathy via effects on the extracellular signal-regulated kinase/mitogen-activated protein kinase and RhoA signaling pathways | Q38605378 |
| | Structural determinants of SHP-2 function and specificity in Xenopus mesoderm induction | Q39631199 |
| | Receptor-specific regulation of phosphatidylinositol 3'-kinase activation by the protein tyrosine phosphatase Shp2. | Q39674852 |
| | Rapamycin regulates Akt and ERK phosphorylation through mTORC1 and mTORC2 signaling pathways | Q39698423 |
| P4510 | describes a project that uses | ImageJ | Q1659584 |
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | hypertrophic cardiomyopathy | Q1364270 |
| | sirolimus | Q32089 |
| P304 | page(s) | 1026-1043 | |
| P577 | publication date | 2011-02-21 | |
| P1433 | published in | Journal of Clinical Investigation | Q3186904 |
| P1476 | title | Rapamycin reverses hypertrophic cardiomyopathy in a mouse model of LEOPARD syndrome-associated PTPN11 mutation | |
| P478 | volume | 121 | |